Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer Academic Article uri icon

Overview

MeSH Major

  • Anti-Bacterial Agents
  • Bacteremia
  • Carbapenems
  • Enterobacteriaceae

abstract

  • Patients with lymphoid cancer receiving ibrutinib treatment are at risk for serious infections, including IFIs.

publication date

  • August 16, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC6093991

Digital Object Identifier (DOI)

  • 10.1093/cid/ciy175

PubMed ID

  • 29509845

Additional Document Info

start page

  • 687

end page

  • 692

volume

  • 67

number

  • 5